3 Result(s)
-
Article
Open AccessModeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective ...
-
Article
Open AccessDownregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs...
-
Article
Open AccessBlood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
Plasma genoty** identifies potentially actionable mutations at variable mutant allele frequencies, often admixed with multiple subclonal variants, highlighting the need for their clinical and functional vali...
